

523,836

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



Rec'd PCT/PTO 07 FEB 2005



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016253 A1

- (51) International Patent Classification⁷: **A61K 31/00**, 31/4985, 31/277, 31/352, 31/223, 31/415, 31/325, 45/06, A61P 31/04, 15/14
- (21) International Application Number: PCT/EP2003/050373
- (22) International Filing Date: 12 August 2003 (12.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02078352.8 14 August 2002 (14.08.2002) EP
- (71) Applicant (*for all designated States except US*): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BOULANGER, Delphine [BE/BE]; c/o Université de Liège, Place du 20-Août 7, B-4000 Liège (BE). BUREAU, Fabrice [BE/BE]; c/o Université de Liège, Place du 20-Août 7, B-4000 Liège (BE). LEKEUX, Pierre [BE/BE]; c/o Université de Liège, Place du 20-Août 7, B-4000 Liège (BE).
- (74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
 - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
 - of inventorship (Rule 4.17(iv)) for US only
- Published:**
- with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS

(57) Abstract: The present invention relates to the use of NF-KB (NF-kappa B) inhibitors for the manufacture of a medicament for the treatment of mastitis.

WO 2004/016253 A1